Success Metrics

Clinical Success Rate
50.0%

Based on 1 completed trials

Completion Rate
50%(1/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Terminated
1(33%)

Phase Distribution

Ph phase_2
1
33%
Ph phase_1
2
67%

Phase Distribution

2

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
2(66.7%)
Phase 2Efficacy & side effects
1(33.3%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

1

trials recruiting

Total Trials

3

all time

Status Distribution
Active(1)
Completed(1)
Terminated(1)

Detailed Status

Terminated1
Active, not recruiting1
Completed1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
1
Success Rate
50.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (66.7%)
Phase 21 (33.3%)

Trials by Status

terminated133%
active_not_recruiting133%
completed133%

Recent Activity

1 active trials
Showing 3 of 3
active_not_recruitingphase_2

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

NCT01697527
completedphase_1

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

NCT02775292
terminatedphase_1

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

NCT02070406

Clinical Trials (3)

Showing 3 of 3 trials
NCT01697527Phase 2

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active Not Recruiting
NCT02775292Phase 1

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

Completed
NCT02070406Phase 1

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Terminated

All 3 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
3